The latter brought in acute myeloid leukaemia (AML) and cholangiocarcinoma therapy Tibsovo (ivosidenib), which was approved as a first-line therapy for AML last year in combination with Bristol ...
bringing the Bristol Myers Squibb-partnered Tibsovo (ivosidenib) for IDH1-mutant acute myeloid leukaemia to the US market. It also shares commercial rights to BMS’ Idhifa (enasidenib), also for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback